SEC Form 4
------------

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington, D.C. 20549															(	APPRO\	/AL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					FINE PROVIDENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												OMB Number: 3235-026 Estimated average burden hours per response: 0			
transac contrac the pur securit to satis conditi	chase or sale of	pursuant to a written plan for f equity that is intended ve defense																		
1. Name and Address of Reporting Person <sup>*</sup> English Emily						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Cartesian Therapeutics, Inc.</u> [ RNAC ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O CARTESIAN THERAPEUTICS, INC. 7495 NEW HORIZON WAY						3. Date of Earliest Transaction (Month/Day/Year) 01/02/2025									☑     Officer (give title below)     Other (specify below)       Chief Operations Officer     Chief Operations Officer					
(Street) FREDERICK MD 21703					4. 1															
(City)	(City) (State) (Zip)																			
Table I - Non-Deriva   1. Title of Security (Instr. 3)   2. Transa   Date (Month/D						ction 2A. Deemed Execution Date			r) 3. 3. 4. Se Disp 5) 5)		4. Securi	urities Acquired (A) ed Of (D) (Instr. 3, 4		A) or	5. Amour Securitie Beneficia	s ally ollowing I ion(s)	Form (D) or	: Direct c r Indirect E str. 4) C	7. Nature of Indirect Beneficial Dwnership Instr. 4)	
Common Stock 01/02/						/2025			A		16,100 A <sup>(1)</sup>		\$ <mark>0</mark>	` <i>`</i>		D				
		-	Table II - I						,		osed of, convertil				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	4. Transaction Code (Instr. 8)				6. Date Expiration (Month/Da	n Date	Э	of Securities		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisat		Expiration Date	Title	or Ni of	umber						
Employee Stock Option (right to buy)	\$16.93	01/02/2025			Α		47,400		(2)		01/01/2035	Commo Stock		7,400	\$0	47,400	)	D		
Explanatio	n of Respons	es:																		

1. Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

2. This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

Remarks:

/s/ Matthew Bartholomae, Attorney-in-Fact for Emily English \*\* Signature of Reporting Person Date

01/06/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.